Stock Ticker

  • Loading stock data...

Pfizer Inc. (NYSE:PFE) And Bristol-Myers Squibb Co (NYSE:BMY) Announced FDA Clearance For Eliquis For Blood Clots Treatment

Boston, MA 08/22/2214 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb Co (NYSE:BMY) announced recently that the USFDA has given an extension of approving Eliquis, the blood thinner, which shall be used for the treatment of fatal blood clots. The treatment of two kinds of blood clots can be done by way of this blood thinner.

FDA Clearance for Drug

The two companies, BMY and Pfizer Inc. (NYSE:PFE), announced that the federal regulator gave its clearance to the drug, especially for patients who are suffering from or are jeopardized because of pulmonary embolism or deep vein thrombosis. At first, Food and Drug Administration had given its approval to this drug in the year 2012 for the treatment of atrial fibrillation and irregular heartbeat form, in the patients who were at an increased risk of not just dangerous clots, but also strokes. Manufactured by Bristol-Myers Squibb Co (NYSE:BMY) and co-marketed by Pfizer Inc. (NYSE:PFE), Eliquis (chemical name- apixaban), has remained the talk of these two New York based pharma companies recently.

Forms of Blood Clots

Deep vein thrombosis usually occurs in situations when blood starts clotting in one of the deep and large veins, primarily in the legs. On the other hand, pulmonary embolism is yet another condition, which usually occurs entire or a few parts of thrombosis shifts from its place and starts travelling to lungs by taking the route of heart. This condition can completely or partially block branch of pulmonary artery.

Interestingly, every year, approximately 900,000 Americans go through the condition of one of the aforementioned clots. Also, this leads to approximately 300,000 deaths.

In terms of the same category, i.e., blood thinner, yet another drug called Xarelto from the rival company Johnson & Johnson (NYSE:JNJ) was given an approval by the federal regulators for treatment of same conditions. This approval was given by the FDA in the year 2012.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at [email protected] or follow Nicholas Kitonyi @nmaithyak on Twitter.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts